By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 10:00.
Grifols (ES0171996087) cut its 2026 EBITDA guidance and continues to trade under the shadow of an accounting probe by Spain’s CNMV, with its main listing in Madrid on the Spanish stock exchange BME. The plasma-derived medicines group now assumes a lower earnings trajectory than previously signaled, according to its latest investor materials and recent press coverage.
What recent reports highlight
The current cautious tone around Grifols stems from allegations about its past reporting of related-party transactions with investment vehicle Scranton Enterprises, which triggered scrutiny by short-seller Gotham City Research in early 2024 and a formal review by the CNMV. Reuters reported that the regulator broadened its review of Grifols’ disclosures and risk controls in the first half of 2024, keeping governance and transparency questions in focus for equity investors. The company has repeatedly defended the integrity of its accounts and engaged KPMG and other advisers to support its responses.
At the same time, Grifols updated its forward guidance following a period of margin pressure and balance-sheet deleveraging, trimming its 2026 EBITDA outlook relative to earlier ambitions. Market commentary notes that the group’s cost base and integration spend after prior acquisitions, together with interest costs on its debt stack, leave limited room for error on the revised targets. For investors on BME and in the broader European health care sector, these developments make Grifols a live case study in how governance and leverage can interact with operational fundamentals.
Analyst stance and consensus
Analyst views on Grifols remain mixed but data from MarketScreener show a split between Buy and Hold recommendations, with only a minority of houses on outright Sell. The average 12?month price target on the Madrid?listed shares sits meaningfully above the current quotation, reflecting expectations of gradual deleveraging and recovery in plasma volumes. Some brokers, including international houses such as UBS and Deutsche Bank, emphasize that any resolution of the CNMV review and greater clarity on related?party reporting could act as a catalyst for rerating. Others stay cautious, pointing to execution risk around the company’s guidance adjustments and its still-elevated net debt to EBITDA levels.
According to recent research summaries, estimates for Grifols’ 2025 and 2026 earnings embed a continued rebound in plasma collections and incremental margin improvement, but not a return to the group’s pre?COVID profitability profile. The consensus also assumes that the company can maintain access to capital markets and refinance upcoming maturities on acceptable terms, a point that depends in part on how quickly governance questions are resolved. For retail investors comparing Grifols with peers such as CSL or Kedrion in the plasma segment, the valuation spread reflects this added uncertainty as much as the underlying business profile.
Go deeper
All news and analysis on the Grifols shares
Further reporting, quotes and regulatory documents on Grifols can be found in the dedicated topic section and via the company’s investor relations hub.
See the Grifols sharesInvestor Relations
The business behind the stock
Grifols generates the bulk of its revenue from plasma-derived biopharmaceuticals used to treat conditions such as immune deficiencies and bleeding disorders, complemented by its diagnostics and hospital divisions. The company operates an extensive network of plasma donation centers, mainly in the United States and Europe, and runs fractionation plants that turn raw plasma into finished therapeutic products. In diagnostics, Grifols supplies blood typing and transfusion solutions to hospitals and blood banks, giving the group a diversified but still health care?concentrated earnings base.
Where the shares trade today
The Grifols shares (ES0171996087) trade on BME Madrid, with recent quotations around 8 euros per share as of the latest available session, according to exchange data. That level leaves the company’s market capitalization in the mid single?digit billion?euro range, positioning Grifols among the larger Spanish health care names but below global plasma peer CSL in terms of equity value.
Key data on the Grifols shares
- Company: Grifols S.A.
- ISIN: ES0171996087
- WKN: 000000
- Ticker: GRF
- Trading venue: BME Madrid
- Price (as of 2026-06-26, 17:35): 8.00 EUR
- Market cap: 5.0 billion EUR (as of 2026-06-26)
- Sector / industry: Health Care / Biotechnology
- Index membership: IBEX 35
- Next earnings date: 2026-07-31
More on the Grifols shares in social media
This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or a solicitation of any offer to buy or sell. All data are based on sources believed to be reliable but may be subject to revision. Investors should conduct their own research or consult a professional advisor before making investment decisions.
en | ES0171996087 | GRIFOLS | boerse | 69652053 | bgmi
